Advances in Bioscience and Biotechnology

Volume 3, Issue 4 (August 2012)

ISSN Print: 2156-8456   ISSN Online: 2156-8502

Google-based Impact Factor: 1.18  Citations  h5-index & Ranking

High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure

HTML  Download Download as PDF (Size: 266KB)  PP. 516-523  
DOI: 10.4236/abb.2012.324068    4,261 Downloads   7,107 Views  Citations

ABSTRACT

Hepatocyte growth factor (HGF) is a renotropic, antifibrotic and regenerative factor with cytoprotective effects that is produced by mesenchymal cells and shows high affinity to components of extra cellular matrix, such as heparan sulphate proteoglycan (HS-PG), in healthy. Patients with chronic renal failure (CRF) suffer from a chronic inflammatory disorder. In order to assess the underlying mechanisms for development of CRF we aimed to assess the amounts and affinity of HGF in this patient group. Elisa, western blot and surface plasmon resonance (SPR) were used to study HGF in blood samples, as well as in isolated neutrophils, in CRF patients compared to healthy controls. Patients with CRF showed higher HGF levels in serum (P < 0.0001), but decreased affinity to HSPG (P < 0.0001), compared to healthy controls. Addition of protease inhibitors decreased the difference between patients with CRF compared to healthy individuals. HGF with potent regenerative function during injury lacks affinity to HSPG in patients with CRF that may depend on production of proteases from activated immune cells. This information might be used to highlight underlying mechanisms for chronicity and leading to new strategies for treatment of chronic injuries.

Share and Cite:

Lönn, J. , Shahzad, F. , Uhlin, F. , Bengtsson, T. , Almroth, G. and Nayeri, F. (2012) High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure. Advances in Bioscience and Biotechnology, 3, 516-523. doi: 10.4236/abb.2012.324068.

Cited by

[1] Targeted biomarkers of progression in chronic kidney disease
Clinica Chimica Acta, 2022
[2] Clinical biobanking and the distinguishing risk of progressive chronic kidney disease study
2021
[3] Dynamic changes of early-stage aortic lipid deposition in chronic renal failure rats and effects of decorin gene therapy
Experimental and therapeutic medicine, 2015
[4] Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: The clinical impact of a rapid diagnostic test for immediate …
Cytokine, 2015
[5] Evaluation of hepatocyte growth factor as a local acute phase response marker in the bowel: The clinical impact of a rapid diagnostic test for immediate identification of acute bowel inflammation
Cytokine, 2015
[6] Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis
Fluids and Barriers of the CNS, 2015
[7] Significance of plasma hepatocyte growth factor in diagnosis of benign and malignant solitary pulmonary nodules
International journal of clinical and experimental pathology, 2015
[8] High Concentration but Low Activity of Hepatocyte Growth Factor in Periodontitis
Journal of periodontology, 2014
[9] Superficial nuclear density of hepatocytes of livers subjected to a humoral stimulating factor in mice
2014
[10] Densidad superficial nuclear de hepatocitos de hígados sometidos a un factor estimulante humoral en ratones
Revista Archivo Médico de Camagüey, 2014
[11] A methachromatic-based experimental model for identification of bowel as the focus of an acute inflammation
Open Journal of Gastroenterology, 2013
[12] Fibroblast Growth Factor 23, Hepatocyte Growth Factor, Interleukin‐6, High‐Sensitivity C‐Reactive Protein and Soluble Urokinase Plasminogen Activator Receptor. Inflammation Markers in Chronic Haemodialysis Patients?
Scandinavian journal of immunology, 2013
[13] Differences in the expression of hepatocyte growth factor in acute and chronic bowel inflammation—Implications for diagnosis?
Advances in Bioscience and Biotechnology, 2013
[14] Differences in the expression of hepatocyte growth factor in acute and chronic bowel inflammation-Implications for diagnosis?
Thesis, 2013
[15] Fibroblast Growth Factor 23, Hepatocyte Growth Factor, Interleukin‐6, High‐Sensitivity C‐Reactive Protein and Soluble Urokinase Plasminogen Activator Receptor …
Scandinavian journal of immunology, 2013

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.